Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran
Suwarni, Riana
Unknown Affiliation
Health Professions

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Amoksisilin versus Kotrimoksazol untuk Mengobati Pneumonia yang Tidak Parah: Tinjauan Sistematis Suwarni, Riana; Nuryanto, Anjar
Cermin Dunia Kedokteran Vol 51 No 8 (2024): Penyakit Dalam
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v51i8.1225

Abstract

Introduction: Pneumonia is still one of the common causes of death in children under 5 years old in low-middle-income countries. The common cause of pneumonia is bacteria, requiring antibiotics as treatment. This systematic review evaluates the efficacy of amoxicillin and cotrimoxazole in treating pneumonia. Methods: This systematic review used PRISMA rules to analyze Pubmed and Europe PMC articles. The dose, duration, and therapeutic failure of amoxicillin and cotrimoxazole were assessed. Results: A total of 336 articles were selected for title and abstract screening. Four articles met the requirements, and two were selected for systematic review analysis. A total of 20,646 patients were analyzed, 11,633 (56.3%) received amoxicillin and 9,013 (43.7%) received cotrimoxazole. There was no significant difference in treatment failure between amoxicillin and cotrimoxazole. Conclusion: Amoxicillin has the same efficacy as cotrimoxazole for the management of non-severe pneumonia in children under 5 years old.
Perbandingan Efek Samping ARNI vs ACEi/ARB pada Terapi Gagal Jantung: Analisis Nuryanto, Anjar; Suwarni, Riana
Cermin Dunia Kedokteran Vol 52 No 5 (2025): Kardiologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v52i5.1314

Abstract

Introduction: Pharmacological treatment of heart failure continues to develop. Newer drugs such as ARNI (angiotensin receptor neprilysin inhibitor) have become standard for heart failure treatment. This systematic review aims to compare the side efects of ARNI with those of previous standard heart failure therapy. Methods: This research uses PRISMA rules to analyze articles from PubMed and Cochrane. Results: A total of 2,741 articles, excluding duplicates, were selected for title and abstract screening. Twelve articles met the requirements for thorough screening. Of the 12 articles, 4 articles were selected for systematic review analysis. There were 6,553 samples, 2,580 in the ARNI group and 2,390 in the ACEI/ARB group. ARNI was better in reducing the risk of decreased eGFR (RR: 0.51; 0.34-0.78) and the incidence of hyperkalemia (RR: 0.87; 0.76-0.99) but the risk of symptomatic hypotension was greater in the ARNI group (RR: 1.47; 1.23-1.70). Conclusion: The risk of hypotension as well as a reduced risk of cardiovascular death and rehospitalization was higher in the ARNI group, while the risk of decreased eGFR and hyperkalemia was higher in the ACEi/ARB group.
Co-Authors Nuryanto, Anjar